Protea Biosciences Group Inc (PRGBQ) financial statements (2021 and earlier)

Company profile

Business Address 1311 PINEVIEW DRIVE
MORGANTOWN, WV 26505
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments00010
Cash and cash equivalents00010
Receivables00000
Inventory, net of allowances, customer advances and progress billings00001
Inventory00001
Prepaid expense0000
Prepaid expense and other current assets0
Other undisclosed current assets   00
Total current assets:10131
Noncurrent Assets
Property, plant and equipment23333
Deposits noncurrent assets  00 
Other noncurrent assets0000
Prepaid expense and other noncurrent assets0
Other undisclosed noncurrent assets  (0)(0) 
Total noncurrent assets:23333
TOTAL ASSETS:33454
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:00211
Accounts payable001  
Accrued liabilities000  
Employee-related liabilities000  
Taxes payable00   
Interest and dividends payable000  
Other undisclosed accounts payable and accrued liabilities   11
Debt41111
Due to related parties331  
Deferred revenue and credits000  
Other undisclosed current liabilities85348
Total current liabilities:16108610
Noncurrent Liabilities
Long-term debt and lease obligation, including:22222
Other undisclosed long-term debt and lease obligation22222
Liabilities, other than long-term debt   1(0)
Customer advances or deposits    (0)
Derivative instruments and hedges, liabilities   1 
Total noncurrent liabilities:22222
Total liabilities:171110812
Stockholders' equity
Stockholders' equity attributable to parent, including:(14)(8)(6)(3)(8)
Preferred stock  0  
Common stock00000
Additional paid in capital8171645538
Accumulated other comprehensive income (loss)00(0)0(0)
Accumulated deficit(95)(80)   
Other undisclosed stockholders' equity attributable to parent  (70)(58)(46)
Total stockholders' equity:(14)(8)(6)(3)(8)
Other undisclosed liabilities and equity    0
TOTAL LIABILITIES AND EQUITY:33454

Income statement (P&L) ($ in millions)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)
22211
Cost of revenue(2)(1)(1)  
Gross profit:11111
Operating expenses(6)(8)(12)(13)(11)
Other undisclosed operating income  011
Operating loss:(5)(7)(11)(10)(9)
Nonoperating expense(10)(2)(1)(1)(1)
Investment income, nonoperating  1  
Interest and debt expense(2)(0)(1)(0)(0)
Loss from continuing operations before equity method investments, income taxes:(18)(10)(12)(11)(10)
Other undisclosed income from continuing operations before income taxes20100
Net loss available to common stockholders, diluted:(16)(10)(11)(11)(10)

Comprehensive Income ($ in millions)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(16)(10)(11)(11)(10)
Comprehensive loss:(16)(10)(11)(11)(10)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0(0)0(0)
Comprehensive loss, net of tax, attributable to parent:(16)(10)(11)(11)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: